DeepTek.ai secures US FDA clearance for groundbreaking Chest X-ray AI solution

DeepTek.ai, a Pune-based medical imaging artificial intelligence (AI)-based startup, has received clearance from the US Food and Drug Administration (FDA) for its revolutionary Chest X-ray AI solution - CXR Analyzer. This advanced technology uses deep learning algorithms to detect abnormalities in chest X-rays. It identifies, categorises, and highlights suspicious areas automatically, aiding clinicians in making precise interpretations. 

Unlike traditional point AI solutions identifying a specific pathology, DeepTek's Chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest. It is compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units making it versatile and powerful. 

This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases. In a world with 3.5 billion annual X-rays, 1.5 billion are chest X-rays, making the need for precise interpretation essential. The shortage of radiologists further emphasises the role of AI in addressing this challenge.

DeepTek's AI solutions have been transforming healthcare in India and the Asia-Pacific region by providing increased access to quality care at a lower cost. Over 500 hospitals and imaging centers are using DeepTek's AI solutions, impacting the lives of 100,000 people monthly. More than half a million people have been screened using DeepTek's Chest X-Ray Analyzer for tuberculosis screening.